TABLE 2.
Amphotericin B, flucytosine, and LY303366 susceptibilities of ATCC 90028 and 21 clinical isolates of C. albicans in RPMI and in human serum
| Isolate | MIC (μg/ml)
|
||
|---|---|---|---|
| Amphotericin B | Flucytosine | LY303366 | |
| ATCC 90028 | |||
| RPMI | 1 | 0.5 | 0.125 |
| Serum | 1 | 2 | 1 |
| CA38 | |||
| RPMI | 2 | 0.125 | 0.25 |
| Serum | 2 | 0.25 | 2 |
| JK23 | |||
| RPMI | 1 | 0.25 | 0.25 |
| Serum | 1 | 0.5 | 2 |
| JK27 | |||
| RPMI | 1 | 0.25 | 0.25 |
| Serum | 1 | 0.5 | 2 |
| JK28 | |||
| RPMI | 1 | 0.5 | 0.125 |
| Serum | 1 | 1 | 1 |
| JK32 | |||
| RPMI | 1 | 1 | 0.125 |
| Serum | 1 | 1 | 1 |
| TO3 | |||
| RPMI | 1 | 0.125 | 0.125 |
| Serum | 1 | 0.5 | 1 |
| TO17 | |||
| RPMI | 1 | 0.125 | 0.125 |
| Serum | 1 | 0.5 | 1 |
| 2-76 | |||
| RPMI | 1 | 0.25 | 0.125 |
| Serum | 1 | 1 | 1 |
| 12-99 | |||
| RPMI | 1 | 1 | 0.125 |
| Serum | 1 | 2 | 4 |